NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free CELC Stock Alerts $21.60 +3.44 (+18.94%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$17.67▼$22.1950-Day Range$14.35▼$18.5652-Week Range$8.39▼$22.19Volume605,554 shsAverage Volume219,042 shsMarket Capitalization$522.72 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Celcuity alerts: Email Address Celcuity MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside34.3% Upside$29.00 Price TargetShort InterestBearish8.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 13 Articles This WeekInsider TradingSelling Shares$4,952 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.76) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 starsMedical Sector525th out of 938 stocksMedical Laboratories Industry12th out of 20 stocks 3.5 Analyst's Opinion Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.00, Celcuity has a forecasted upside of 34.3% from its current price of $21.60.Amount of Analyst CoverageCelcuity has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.31% of the outstanding shares of Celcuity have been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Celcuity has recently decreased by 0.99%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELC. Previous Next 2.9 News and Social Media Coverage News SentimentCelcuity has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Celcuity this week, compared to 1 article on an average week.Search Interest1 people have searched for CELC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Celcuity to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,952.00 in company stock.Percentage Held by Insiders24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($2.76) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Celcuity Stock (NASDAQ:CELC)Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Read More CELC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELC Stock News HeadlinesMarch 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)March 28, 2024 | finance.yahoo.comQ4 2023 Celcuity Inc Earnings CallMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 27, 2024 | finance.yahoo.comCelcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key DevelopmentsMarch 27, 2024 | benzinga.comRecap: Celcuity Q4 EarningsMarch 27, 2024 | globenewswire.comCelcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 20, 2024 | globenewswire.comCelcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference CallMarch 15, 2024 | finance.yahoo.comCELC Apr 2024 20.000 callMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 6, 2024 | globenewswire.comCelcuity to Participate in Leerink Partners Global Biopharma Conference 2024February 28, 2024 | finance.yahoo.comCelcuity to Participate in Cowen’s 44th Annual Health Care ConferenceFebruary 28, 2024 | globenewswire.comCelcuity to Participate in Cowen's 44th Annual Health Care ConferenceFebruary 25, 2024 | msn.comCelcuity (CELC) Price Target Increased by 12.99% to 27.95February 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Celcuity (CELC)February 23, 2024 | msn.comStifel Initiates Coverage of Celcuity (CELC) with Buy RecommendationFebruary 22, 2024 | msn.comStifel starts Celcuity at buy, sees gedatolisib as potential blockbusterFebruary 22, 2024 | finance.yahoo.comCelcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate CancerFebruary 20, 2024 | finanznachrichten.deCelcuity Inc.: Celcuity Appoints Eldon Mayer as Chief Commercial OfficerFebruary 20, 2024 | finance.yahoo.comCelcuity Appoints Eldon Mayer as Chief Commercial OfficerFebruary 20, 2024 | globenewswire.comCelcuity Appoints Eldon Mayer as Chief Commercial OfficerJanuary 22, 2024 | finance.yahoo.comCelcuity Inc. (NASDAQ:CELC) has caught the attention of institutional investors who hold a sizeable 33% stakeJanuary 11, 2024 | fool.comCelcuity (NASDAQ: CELC)December 9, 2023 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Celcuity (CELC) with Buy RecommendationDecember 8, 2023 | benzinga.comCelcuity Stock (NASDAQ:CELC), Analyst Ratings, Price Targets, PredictionsDecember 6, 2023 | finance.yahoo.comCelcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer SymposiumDecember 1, 2023 | finance.yahoo.comCelcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer SymposiumNovember 22, 2023 | finance.yahoo.comCelcuity to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceSee More Headlines Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CELC CUSIPN/A CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Stock Price Target$30.33 High Stock Price Target$40.00 Low Stock Price Target$24.00 Potential Upside/Downside+47.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.14% Return on Assets-35.52% Debt Debt-to-Equity Ratio0.39 Current Ratio11.15 Quick Ratio11.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book3.30Miscellaneous Outstanding Shares24,200,000Free Float18,322,000Market Cap$492.47 million OptionableOptionable Beta0.74 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Brian F. Sullivan (Age 62)Co-Founder, Chairman & CEO Comp: $105.77kDr. Lance G. Laing Ph.D. (Age 62)Co-Founder, Chief Science Officer, VP, Secretary & Director Comp: $325.38kMs. Vicky Hahne (Age 58)Chief Financial Officer Comp: $210kDr. John R. MacDonald Dabt (Age 69)Ph., Ph.D., Senior Vice President of R&D Ms. Sheri SmithActing Head of Clinical OperationsMr. Igor Gorbatchevsky M.D.Chief Medical OfficerMr. Eldon C. Mayer III (Age 63)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsCareDxNASDAQ:CDNASera PrognosticsNASDAQ:SERACastle BiosciencesNASDAQ:CSTLFulgent GeneticsNASDAQ:FLGTHH&L AcquisitionNYSE:HHLAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 29,181 shares on 3/11/2024Ownership: 3.392%Perceptive Advisors LLCBought 1,481,300 shares on 2/26/2024Ownership: 6.121%Richard E BullerSold 350 sharesTotal: $4,952.50 ($14.15/share)Vanguard Group Inc.Bought 29,181 shares on 2/15/2024Ownership: 3.392%Nuveen Asset Management LLCBought 8,603 shares on 2/15/2024Ownership: 0.134%View All Insider TransactionsView All Institutional Transactions CELC Stock Analysis - Frequently Asked Questions Should I buy or sell Celcuity stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CELC shares. View CELC analyst ratings or view top-rated stocks. What is Celcuity's stock price target for 2024? 4 equities research analysts have issued 1-year target prices for Celcuity's stock. Their CELC share price targets range from $24.00 to $40.00. On average, they expect the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View analysts price targets for CELC or view top-rated stocks among Wall Street analysts. How have CELC shares performed in 2024? Celcuity's stock was trading at $14.57 at the beginning of 2024. Since then, CELC shares have increased by 48.2% and is now trading at $21.60. View the best growth stocks for 2024 here. When is Celcuity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CELC earnings forecast. How were Celcuity's earnings last quarter? Celcuity Inc. (NASDAQ:CELC) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.09. During the same period last year, the company posted ($0.75) EPS. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID). When did Celcuity IPO? Celcuity (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. Who are Celcuity's major shareholders? Celcuity's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Commodore Capital LP (7.25%), Perceptive Advisors LLC (6.12%), Vanguard Group Inc. (3.39%), Vanguard Group Inc. (3.39%), Northern Trust Corp (0.76%) and PFM Health Sciences LP (0.65%). Insiders that own company stock include Brian F Sullivan, David Dalvey, Richard E Buller and Richard Nigon. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.